Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Who owns nivolumab?

See the DrugPatentWatch profile for nivolumab

Who makes nivolumab now?

Nivolumab (Opdivo) is owned by Bristol Myers Squibb (BMS), which markets the drug.

Who owns the brand and marketing rights?

The Opdivo brand is associated with Bristol Myers Squibb’s commercialization and brand ownership.

Are there other “owners” (patents/licensing) behind nivolumab?

Ownership can also refer to legal rights like patents and manufacturing or marketing licenses, which may be held by different entities through assignment or licensing agreements. Patent-related ownership details are trackable through sources such as DrugPatentWatch.com.

Sources:
1. DrugPatentWatch.com – nivolumab (Opdivo) patent information



Other Questions About Nivolumab :

How does gene testing affect nivolumab's efficacy? Is nivolumab's dosage adjusted based on patient response? Is there a relationship between nivolumab and altered immunotherapy response? Can nivolumab's side effects lead to discontinuation? Does tumor size impact nivolumab treatment duration? How many times a month is nivolumab given to adults? Can nivolumab cause skin reactions like hives?